Physician profile
Elizabeth Ducat
NPI 1306151279
$2,859.53
in general payments reported to CMS, 2019-2025
11 companies · $43.68 in 2025
The $43.68 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $578 · 2022: $747 · 2023: $772 · 2024: $719 · 2025: $43.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.26 | 2021-2025 | |
| Lundbeck LLC | $558.93 | 2021-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $538.01 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $354.54 | 2022-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $337.03 | 2021-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $296.09 | 2021-2024 | Trintellix |
| Almatica Pharma LLC | $93.93 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $38.75 | 2024 | Cobenfy |
| Corium, LLC | $20.78 | 2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $16.78 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Ducat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.